Starpharma Holdings EPS - Earnings per Share 2011-2021 | SPHRY
Starpharma Holdings eps - earnings per share from 2011 to 2021. Eps - earnings per share can be defined as a company's net earnings or losses attributable to common shareholders per diluted share base, which includes all convertible securities and debt, options and warrants.
| Starpharma Holdings Annual EPS |
| 2021 |
$-0.37 |
| 2020 |
$-0.27 |
| 2019 |
$-0.29 |
| 2018 |
$-0.23 |
| 2017 |
$0.15 |
| 2016 |
$-0.51 |
| 2015 |
$-0.50 |
| 2014 |
$-0.47 |
| 2013 |
$-0.21 |
| 2012 |
$-0.52 |
| 2011 |
$0.00 |
| Starpharma Holdings Quarterly EPS |
| 2021-06-30 |
$0.00 |
| 2020-12-31 |
$0.00 |
| 2020-06-30 |
$0.00 |
| 2019-12-31 |
$0.00 |
| 2019-06-30 |
$0.00 |
| 2018-06-30 |
$0.00 |
| 2017-12-31 |
$0.00 |
| 2017-06-30 |
$0.00 |
| 2016-12-31 |
$0.00 |
| 2016-06-30 |
$0.00 |
| 2015-06-30 |
$0.00 |
| 2014-12-31 |
$0.00 |
| 2014-06-30 |
$0.00 |
| 2013-12-31 |
$0.00 |
| 2013-06-30 |
$0.00 |
| 2012-12-31 |
$0.00 |
| 2012-06-30 |
$0.00 |
| 2011-12-31 |
$0.00 |
| 2011-06-30 |
$0.00 |
| 2010-12-31 |
$0.00 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.216B |
$0.002B |
|
Starpharma Holdings Limited is engaged in the development of dendrimer products for pharmaceutical, life science and other applications. The Company's primary product in development is VivaGel, a microbicide gel for women used for the prevention and treatment of bacterial vaginosis and a range of sexually transmitted diseases. It also develops dendrimers as specialty chemicals for industrial applications. Starpharma Holdings Limited is headquartered in Melbourne, Australia.
|
